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ABSTRACT
Background: Elevated plasma low-density lipoprotein cholesterol (LDL-C) 
concentrations are highly atherogenic, especially the small, dense LDL (sdLDL) spe-
cies. Fenofibrate has been reported to shift the LDL profile by decreasing the sdLDL 
subfraction and increasing larger LDL subclasses. Atorvastatin, an antihyperlipidemic 
agent, has been reported to reduce plasma total cholesterol (TC) and triglyceride (TG) 
concentrations and thus could modify the LDL profile.
Objective: The aim of this study was to compare the effects of fenofibrate and 
atorvastatin on standard lipid concentrations and the LDL profile.
Methods: In this randomized, open-label, parallel-group study, men and wom-
en aged 18 to 79 years with type II primary dyslipidemia, defined as LDL-C ≥160 and 
TG 150 to 400 mg/dL, after a 4- to 6-week washout period while eating an appropri-
ate diet, were randomized to receive either atorvastatin 10 mg once daily or fenofi-
brate 200 mg once daily. Plasma lipid concentrations and cholesterol and apolipopro-
tein (apo) B (reflecting the LDL particle number) in each LDL subfraction prepared 
by ultracentrifugation were determined at baseline and after 12 weeks of treatment. 
Tolerability was assessed using adverse events (AEs) obtained on laboratory analysis 
and vital sign measurement. Adherence was assessed by counting unused drug 
supplies.
Results: A total of 165 patients (117 men, 48 women; mean [SD] age, 
50.1 [10.7] years; mean TC concentration, 289 mg/dL) were randomized to receive 
atorvastatin (n = 81) or fenofibrate (n = 84). Compared with fenofibrate, atorvastatin 
was associated with a significantly greater mean (SD) percentage decrease in TC 
(27.0% [12.3%] vs 16.5% [12.9%]; P < 0.001), calculated LDL-C (35.4% [15.8%] 
vs 17.3% [17.2%]; P < 0.001), TC/high-density lipoprotein cholesterol (HDL-C) 
ratio (29.1% [16.3%] vs 22.9% [15.9%]; P = 0.001), and apoB (30.3% [12.7%] vs 
19.6% [15.5%]; P < 0.001). Compared with atorvastatin, fenofibrate was associated 
with a significantly greater decrease in TG (37.2% [25.9%] vs 20.2% [27.3%]; P < 
0.001) and a significantly greater increase in HDL-C concentration (10.4% [15.7%] 
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vs 4.6% [12.1%]; P = 0.017). Fibrinogen concentration was significantly different be-
tween the 2 groups (P = 0.002); it was decreased with fenofibrate use (4.6% [23.7%]) and 
was increased with atorvastatin use (5.7% [23.5%]). Atorvastatin did not markedly affect 
the LDL distribution; it was associated with a homogeneous decrease in cholesterol and 
apoB concentrations in all subfractions, whereas fenofibrate was associated with a marked 
movement toward a normalized LDL profile, shifting the sdLDL subfractions toward 
larger and less atherogenic particles, particularly in those patients with baseline TG 
≥200 mg/dL. No serious AEs related to the study treatments were reported. A total of 
5 AEs were observed in 8 patients, including: abdominal pain, 3 patients (2 in the atorva-
statin group and 1 in the fenofibrate group); abnormal liver function test results, 1 (feno-
fibrate); increased creatine phosphokinase activity, 2 (atorvastatin); gastrointestinal disor-
ders, 1 (fenofibrate); and vertigo, 1 (fenofibrate).
Conclusion: In these dyslipidemic patients, fenofibrate treatment was associ-
ated with an improved LDL subfraction profile beyond reduction in LDL-C, particularly 
in patients with elevated TG concentration, whereas atorvastatin was associated with 
equally reduced concentrations of cholesterol and apoB in all LDL subfractions inde-
pendent of TG concentrations.  (Curr Ther Res Clin Exp. 2009;70:71–93) © 2009 
Excerpta Medica Inc.
Key words: LDL profile, small dense LDL particles, fenofibrate, atorvastatin.
INTRODUCTION
Elevated circulating concentrations of plasma low-density lipoprotein cholesterol 
(LDL-C) are involved in the formation of atheromatous plaque and constitute a major 
risk factor for premature coronary artery disease.
Plasma LDL-C is highly heterogeneous in terms of size, density, chemical composi-
tion, and physicochemical properties. LDL subclasses can be isolated using different 
methods.1–4 In the Framingham Offspring Study,5,6 gradient gel electrophoresis (GGE) 
was used to separate 7 LDL subclasses. According to McNamara’s5 convention, LDL 
subclasses 4 to 7 are small and dense (sdLDL), whereas LDL subclasses 1 to 3 are large 
and less dense.
Patients with coronary artery disease have an increased prevalence of sdLDL.7–12 
These sdLDL particles are also increased in diabetes mellitus,13 familial combined 
hyperlipidemia,14 and mixed dyslipidemia,15,16 which are commonly associated with 
coronary artery disease. An increased proportion of sdLDL particles has also been as-
sociated with marked alterations in plasma lipoprotein and lipid concentrations, such 
as elevated triglyceride (TG) and apolipoprotein (apo) B concentrations and reduced 
high-density lipoprotein cholesterol (HDL-C) and apoA1 concentrations,17 all of 
which are highly predictive of an increased risk for coronary artery disease.7,17,18 The 
epidemiologic Quebec Cardiovascular Study19 found that the increased coronary 
artery disease risk attributable to variations in LDL particle size was partly indepen-
dent of the concomitant variation in plasma lipoprotein and lipid concentrations20,21 
and largely related to a preferential accumulation of sdLDL particles.21 The total 
cholesterol (TC) in LDL particles with a diameter <255 Å was found to have the 
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strongest association with risk for cardiovascular events, with a relative risk of 4.6 in 
the upper tertile compared with the lowest tertile. Conversely, in a case-control study 
(n = 837; 416 cases and 421 controls) nested in CARE (Clinical Assessment of the 
Reliability of the Examination),22 a prevention study with pravastatin conducted in 
4159 survivors of myocardial infarction, large LDL particle size was an independent 
predictor of recurrent cardiovascular events in the control group, with a relative risk 
of 4.0 (95% CI, 1.81–8.82) in the upper quintile (>263 Å) and the lowest quintile 
(<247 Å).
It has been hypothesized that the atherogenicity of sdLDL particles is explained by 
their greater susceptibility to oxidative changes and their increased ability to enter the 
subendothelial space. It is possible for oxidized LDL to be captured by macrophages 
and become cytotoxic.23
Fibrates are known to stimulate lipoprotein lipase activity and consequently to 
increase lipolysis of very low-density lipoproteins (VLDLs), particularly large VLDLs 
that are considered precursors of sdLDL.24 In a short-term, randomized, placebo-
controlled study25 in 32 hypercholesterolemic patients with type 2 diabetes mellitus, 
fenofibrate 200 mg/d was reported to shift the LDL subfraction profile by reducing 
the LDL 3 subfraction (ie, sdLDL subclass) by 51%, whereas larger LDL particles were 
increased. To date, there is no evidence that fenofibrate reduces mortality.
According to a review by Rizzo and Berneis,26 inhibitors of 3-hydroxy-3- 
methylglutaryl coenzyme A reductase (“statins”), believed to reduce mortality, have 
been found to have a less consistent effect on preferential reduction in sdLDL, and 
most studies have found a uniform reduction in all LDL subfractions, whereas others 
reported a larger reduction in sdLDL in hypertriglyceridemic patients.
Atorvastatin is a synthetic statin that reduces plasma cholesterol concentrations 
by inhibiting endogenous cholesterol synthesis.27 This compound has also been 
found to reduce plasma TG concentrations (–26% with 10 mg and –29% with 20 mg 
atorvastatin), but to a lesser extent than fenofibrate (–39%) in patients with com-
bined hyperlipidemia.28
Because of the unique properties claimed for atorvastatin, in terms of both LDL 
lipoproteins and TG-rich particles, comparing its effect on the qualitative changes in 
LDL lipoproteins with those of fenofibrate, particularly in terms of the reduction in 
sdLDL particle number and cholesterol content, is of interest. The aim of this large, 
randomized, parallel-group study was to compare the effects of fenofibrate and ator-
vastatin at the most commonly indicated doses in France in patients with type II 
dyslipidemia. The study design allowed the assessment of qualitative changes in LDL 
profile in terms of numbers of particles and their content and as a function of baseline 
TG concentration.
PATIENTS AND METHODS
Study Population
Patients were recruited by general practitioners in 9 regions in France. All pa- 
tients provided written informed consent before enrollment. Eligible patients were 
men and women aged 18 to 79 years with type II primary dyslipidemia, defined as 
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LDL-C ≥160 and TG 150 to 400 mg/dL, after a 4- to 6-week washout period while 
eating an appropriate diet. 
Patients were excluded from participation if they had any of the following 
conditions: type I, III, IV, or V dyslipidemia; treated or untreated type 1 or 2 dia-
betes mellitus; pancreatitis; gallbladder disease; active peptic ulcer; or a history 
of myocardial infarction, cerebrovascular accident, unstable angina pectoris, or 
any severe life-threatening disease. They were also excluded if they had aspartate 
aminotransferase (AST) or alanine aminotransferase (ALT) activities >2 × the upper 
limit of normal (ULN), γ-glutamyl transpeptidase activity >2 × ULN, creatine 
phosphokinase (CK) activity >2 × ULN, creatinine concentration >133 μmol/L 
(1.5 mg/dL), or thyroid-stimulating hormone concentration >4 μIU/L. Patients 
receiving hormone replacement therapy, thiazide diuretics, corticosteroids, retin-
oids, antivitamin K, cyclosporine, erythromycin, digoxin, or antifungal drugs 
were not eligible for the study. Patients were also excluded if they were pregnant 
or breastfeeding.
Eligibility was assessed after a 4- to 6-week period that included instruction re-
garding a suitable hypolipidemic diet (based on the National Cholesterol Education 
Program29) and washout of previous hypolipidemic treatments.
Study Design
For this study, a multicenter, randomized, open-label, parallel-group design was 
used. The protocol was reviewed and approved by the Comité Consultatif de Protec-
tion des Personnes se prêtant à une Recherche Biomédicale (Nantes, France), an inde-
pendent ethics committee, and was conducted in accordance with quality standards of 
Good Clinical Practice30 and the Declaration of Helsinki.31 Compensation was in ac-
cordance with French law, which permits monetary payment to the investigators but 
prohibits compensation for patients/participants. 
After the washout period, eligible patients were randomized to receive atorvastatin 
10 mg/d or fenofibrate 200 mg/d. Randomization was centralized to reduce the pos-
sible biases of an open-label study. Moreover, the efficacy parameter measurements 
were centralized, and investigators and participants were blinded to lipid values 
(except for data regarding inclusion and prerandomization tests). Treatments were 
administered PO once daily with breakfast over a 10- to 12-week period. Patients 
were instructed to continue their hypolipidemic diet throughout the treatment 
period. Adherence was assessed by counting unused drug supplies.
Blood Collection and Lipid Analysis
Blood samples were collected after a 12-hour fast at baseline and after 6 and 
12 weeks (end of study) of treatment. All biologic assays were centrally performed 
at Institut Pasteur (Lille, France) using previously described methods.32 Blood 
lipid concentrations and fibrinogen were assayed at baseline and after 6 and 
12 weeks of treatment. TC and TG concentrations were determined using enzy-
matic methods using commercial kits in an automatic analyzer (Boehringer In-
gelheim, Ingelheim am Rhein, Germany). HDL-C concentration was determined 
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enzymatically after phosphotungstic acid precipitation. LDL-C concentration was 
calculated with Friedewald’s formula.33 ApoA1 and apoB were assessed using im-
munonephelometry. ApoCIII was assessed using electroimmunoassay.
The LDL particle profile was determined at baseline and at the end of the study 
using ultracentrifugation. LDL particle subfractions for the determination of choles-
terol (LDL-C) and apoB (LDL apoB) concentrations were grouped in 5 major subfrac-
tions: LDL 1 (density 1.019–<1.023 g/mL), LDL 2 (density 1.023–<1.029 g/mL), 
LDL 3 (density 1.029–<1.039 g/mL), LDL 4 (density 1.039–<1.050 g/mL), and LDL 5 
(density 1.050–1.063 g/mL). Fibrinogen was analyzed in frozen samples using chro-
nometric assay.
Efficacy End Points
The efficacy end points were the percentage changes from baseline to the end of the 
study in the concentrations of TC and apoB and in the ratio of cholesterol/apoB in 
each LDL subfraction. In addition, the percentages represented by each LDL subfrac-
tion were analyzed for cholesterol and apoB concentrations. The changes in plasma 
concentrations of standard lipid parameters (TC, TG, calculated LDL-C, HDL-C, TC/
HDL-C ratio, apoA1, apoB, and apoC-III) and fibrinogen were also compared between 
the 2 groups.
Tolerability End Points
In all patients, tolerability was assessed using adverse events (AEs), self-reported or 
collected by interview at each visit, laboratory measurements, and vital signs. Only 
treatment-emergent AEs (TEAEs) (ie, AEs beginning after randomization) were de-
scribed. The relationship to study treatment of all TEAEs was rated by the investiga-
tors as none, uncertain, possible, or probable. Biologic AEs of interest were monitored in 
the study, including increased AST, ALT, and CK activity >3 × ULN, creatinine con-
centration ≥44.2 μmol/L (0.5 mg/dL), and creatinine concentration ≥176.8 μmol/L 
(2.0 mg/dL).
Statistical Analysis
LDL profile was analyzed in all randomized patients who were assessed at end of 
study (modified intent-to-treat population), as the LDL profile was determined twice 
(at baseline and at the end of the study). Analyses of standard lipid concentrations 
were analyzed in all randomized patients using the last-observation-carried-forward 
method (intent-to-treat population).
The efficacy criteria were compared between the 2 treatment groups using the 
Mann-Whitney-Wilcoxon test.
The percentage changes from baseline to the end of the study in concentrations 
of cholesterol and apoB in each LDL subfraction were described according to TG 
concentration at baseline (normotriglyceridemia [TG <200 mg/dL] vs hypertri- 
glyceridemia [TG ≥200 mg/dL]). P < 0.05 was considered significant. Statistical 
analysis was performed with SAS version 9.1 (SAS Institute Inc., Cary, North 
Carolina).
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RESULTS
Patients
A total of 599 patients were enrolled and entered the washout period. Of this num-
ber, 434 were withdrawn before randomization (422 did not meet inclusion criteria, 
10 withdrew consent, 1 due to an AE, and 1 due to an undisclosed reason). The re-
maining 165 patients were randomized and received treatment (81 receiving atorva-
statin and 84 receiving fenofibrate). Of this number, 161 patients completed the study 
(79 receiving atorvastatin and 82 receiving fenofibrate) (Figure 1) and 151 (76 re- 
ceiving atorvastatin and 75 receiving fenofibrate) underwent biologic assessment for 
the LDL profile at the end of the study.
Baseline demographic and clinical characteristics of the 165 patients (117 men, 
48 women; mean [SD] age, 50.1 [10.7] years) are shown in Table I. No significant 
between-group differences in these characteristics were found.
Baseline plasma concentrations of standard lipids (Table II), cholesterol concen- 
tration of LDL subfractions (Table III), and apoB concentration (Table IV), reflect- 
ing the number of LDL particles in each subfraction, were assessed. No significant 
between-group differences in baseline plasma lipid concentrations were found. 
Efficacy
Before treatment, the analysis of the LDL subfraction profile based on cholesterol 
content revealed a net asymmetry, with a greater concentration of sdLDL (LDL 4 and 
5) compared with the lower-density subfractions (Figure 2). Analysis based on apoB 
content led to similar results: in the atorvastatin and fenofibrate groups, the mean 
(SD) proportions of sdLDL were 55.3% (10.7%) and 54.3% (13.8%), respectively 
(Table V). 
Statistically significant differences were found in percentage changes in plasma 
concentrations of standard lipids, lipoproteins, and fibrinogen between the 2 treat-
ment groups (Table II). Atorvastatin use was associated with significantly greater 
mean percentage decreases than fenofibrate in TC (27.0% [12.3%] vs 16.5% [12.9%]; 
P < 0.001), calculated LDL-C (35.4% [15.8%] vs 17.3% [17.2%]; P < 0.001), TC/
HDL-C ratio (29.1% [16.3%] vs 22.9% [15.9%]; P = 0.001), and apoB (30.3% 
[12.7%] vs 19.6% [15.5%]; P < 0.001). Fenofibrate was associated with a signifi-
cantly greater decrease than atorvastatin in TG (37.2% [25.9%] vs 20.2% [27.3%]; 
P < 0.001) and a significantly greater increase in HDL-C concentration (10.4% 
[15.7%] vs 4.6% [12.1%]; P = 0.017). Fibrinogen concentration was significantly 
different between the 2 groups (P = 0.002); it was decreased with fenofibrate use 
(4.6% [23.7%]) and was increased with atorvastatin use (5.7% [23.5%]). Changes in 
concentrations of apoA1 and apoCIII were not significantly different between the 
2 groups.
The percentage changes in cholesterol (Table III) and apoB (Table IV) concentra-
tions were significantly different between groups in most LDL subfractions. Atorva-
statin use was associated with a similar median percentage decrease in cholesterol 
concentrations in all LDL subfractions (29.8%–38.2%). Fenofibrate use was associated 
with median increases in cholesterol concentrations of LDL 2 and 3 subfractions 
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(10.2% and 17.3%, respectively) and decreases in LDL 1, 4, and 5 subfractions 
(18.2%, 26.1%, and 42.0%, respectively). The between-group differences in the per-
centage changes in the subfractions were statistically significant for LDL 1, 2, and 3 
(all, P < 0.001), LDL 4 (P = 0.021), and the sum of the subfractions (P < 0.001), but 
not for LDL 5 (Table III).
Atorvastatin use was associated with a similar percentage decrease in apoB concen-
tration in all LDL subfractions (25.4%–33.6%). In the fenofibrate-treated patients, 
overall median apoB concentration was decreased by 12.3% due to median increases 
Patients enrolled (599)
Patients withdrawn (434)
  Did not meet inclusion criteria (422)
  Withdrew consent (10) 
  Due to AE (1)
  Due to undisclosed reason (1)
Patients randomized
and treated (165)
Atorvastatin 10 mg
(81)
Fenofibrate 200 mg
(84)
Patients withdrawn
between 6 and 12 weeks
  Due to AE (2)
Patients withdrawn
between 6 and 12 weeks
  Withdrew consent (1) 
  Due to AE (1)
Atorvastatin
completed
12 weeks
(79)
Fenofibrate
completed
12 weeks
(82)
Figure 1.  Flow diagram of the study design. AE = adverse event.
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in LDL 2 (13.4%) and LDL 3 (15.0%) and decreases in LDL 1 (6.4%), LDL 4 (23.6%), 
and LDL 5 (38.1%) subfractions. The between-group differences in the subfractions 
were statistically significant for LDL 1, 2, and 3, and the sum of the subfractions (all, 
P < 0.001) (Table IV).
The LDL distribution was not found to be significantly affected by 12 weeks 
of treatment with atorvastatin. In contrast, fenofibrate treatment was associated 
with normalization of the LDL profile; the median proportions of LDL 4 and 
5 subfractions were decreased (3.3% and 7.0%, respectively) and the proportions 
of LDL 1, 2, and 3 subclasses were increased (0.7%, 3.6%, and 7.4%, respectively) 
(Table V). Therefore, after atorvastatin treatment, the proportion of sdLDL still 
represented 50.3% of the particle number compared with 43.3% after fenofibrate 
treatment. 
Atorvastatin and fenofibrate also differed in their effects on the cholesterol/apoB 
ratio in each LDL subfraction. Atorvastatin was associated with a decrease in the ratio 
in all subfractions, suggesting it reduced particle cholesterol content to a larger extent 
than their number, whereas fenofibrate was associated with a significant decrease in this 
ratio in the LDL 1 and 5 subfractions (Figure 3). The difference in the cholesterol/ 
apoB ratio was statistically significant between the atorvastatin and fenofibrate groups 
for LDL 2 (decrease of 5.6 vs decrease of 2.1; P < 0.05) and LDL 3 (decrease of 4.6 vs 
increase of 0.9; P < 0.05).
Table I.  Baseline demographic and clinical characteristics of the study patients receiv-
ing atorvastatin 10 mg/d or fenofibrate 200 mg/d for up to 12 weeks.*
 Atorvastatin Fenofibrate 
Characteristic (n = 81) (n = 84) P
Age, mean (SD), y 49.4 (10.7) 50.8 (10.7) 0.507
Sex, no. (%)
  Male 59 (72.8) 58 (69.0) 0.592
  Female 22 (27.2) 26 (31.0)
BMI, mean (SD), kg/m2 27.1 (3.3) 28.0 (3.8) 0.187
Risk factors, no. (%)
  Hypertension 40 (49.4) 44 (52.4) –
  Current smoker 27 (33.3) 28 (33.3) –
  Personal history of ischemic heart disease 3 (3.7) 1 (1.2) –
  Family history of ischemic heart disease 16 (19.8) 17 (20.2) –
  Diabetes mellitus 2 (2.5)† 0 –
  HDL-C <35 mg/dL (<0.9 mmol/L) 9 (11.1) 7 (8.3) –
BMI = body mass index; HDL-C = high-density lipoprotein cholesterol.
* No significant between-group differences were found (t test or Wilcoxon signed rank sum test for 
quantitative variables; Wilcoxon signed rank sum test, χ2, or Fisher exact test for qualitative 
variables).
† Deviation from the study inclusion/exclusion criteria.
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Table II.  Plasma concentrations of standard lipid parameters and fibrinogen at baseline 
and at the end of the study (last observation carried forward). Values are mg/dL 
unless otherwise specified.
 Atorvastatin 10 mg/d Fenofibrate 200 mg/d 
  (n = 81) (n = 84)
Parameter Baseline % Change Baseline % Change P*
TC
  Mean (SD) 291.5 (35.8) –27.0 (12.3) 286.2 (35.1) –16.5 (12.9) <0.001
  Median 288 –28.7 283.5 –16.7
  95% CI – –30.3 to –26.3 – –20.8 to –13.3
TG
  Mean (SD) 221.8 (55.1) –20.2 (27.3) 228.5 (58.1) –37.2 (25.9) <0.001
  Median 214 –23.1 220 –41.5
  95% CI – –28.7 to –16.9 – –49.5 to –36.2
LDL-C
  Mean (SD) 200.6 (32.1) –35.4 (15.8) 194.5 (31.9) –17.3 (17.2) <0.001
  Median 194 –36.9 195.5 –16.1
  95% CI – –40.8 to –34.4 – –22.0 to –13.2
HDL-C
  Mean (SD)   46.5 (11.8)     4.6 (12.1)  45.9 (10.6)   10.4 (15.7) 0.017
  Median 44.0 2.8 44.0 10.3
  95% CI – 1.8 to 8.2 – 3.8 to 15.4
TC/HDL-C ratio
  Mean (SD)   6.5 (1.4) –29.1 (16.3)  6.5 (1.3) –22.9 (15.9) 0.001
  Median 6.5 –32.8 6.4 –24.5
  95% CI – –35.5 to –29.2 – –28.1 to –20.7
ApoA1
  Mean (SD) 140.4 (23.2)     2.1 (11.3) 141.6 (19.4)    3.7 (11.7) 0.595
  Median 137.0 3.0 139.5 2.9
  95% CI – 0.7 to 5.9 – –1.4 to 6.0
ApoB
  Mean (SD) 153.3 (20.5) –30.3 (12.7) 146.7 (20.6) –19.6 (15.5) <0.001
  Median 150 –30.4 148 –21.7
  95% CI – –34.4 to –27.9 – –24.7 to –17.4
ApoClll
  Mean (SD)   38.6 (13.8)   –6.3 (11.8)  36.9 (10.9)   –8.9 (10.8) 0.157
  Median 36.4 –5.4 35.9 –8.3
  95% CI – –7.9 to –1.8 – –11.9 to –5.8
Fibrinogen
  Mean (SD) 302.2 (71.3)     5.7 (23.5) 285.3 (59.9)   –4.6 (23.7) 0.002
  Median 295 2.8 284.5 –6.1
  95% CI – –0.6 to –6.2 – –12.4 to –3.1
TC = total cholesterol; TG = triglycerides; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-
density lipoprotein cholesterol; Apo = apolipoprotein.
*Mann-Whitney-Wilcoxon test comparing percentage changes between groups.
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0 Table III.  Concentrations of each low-density lipoprotein (LDL) subfraction at baseline and at the end of the study. Values are mg/dL.
 Atorvastatin 10 mg/d Fenofibrate 200 mg/d 
 (n = 76) (n = 75)
Subfraction* Baseline End of Study % Change Baseline End of Study % Change P†
LDL 1
  Mean (SD) 18.8 (7.5) 12.4 (5.6) –32.7 (25.6) 22.7 (27.1) 15.1 (4.2) –18.2 (28.0) <0.001
  Median 17.7 12.0 –36.5 18.1 15.3 –18.2
  95% CI – – –40.3 to –29.2 – – –26.6 to –9.0
LDL 2
  Mean (SD) 18.8 (10.5) 12.9 (6.5) –28.6 (26.4) 23.0 (34.3) 20.1 (6.4) 14.1 (40.9) <0.001
  Median 16.5 11.5 –37.0 16.7 18.8 10.2
  95% CI – – –40.5 to –30.5 – –  2.4 to 15.9
LDL 3
  Mean (SD) 34.6 (15.4) 24.3 (11.4) –26.6 (27.7) 32.8 (16.3) 36.9 (14.0) 33.9 (72.4) <0.001
  Median 30.5 23.0 –29.8 29.4 35.9 17.3
  95% CI – – –41.7 to –21.0 – –  1.4 to 36.2
LDL 4
  Mean (SD) 48.0 (12.9) 30.1 (11.7) –32.0 (28.5) 44.0 (12.7) 35.3 (17.4) –17.6 (37.5) 0.021
  Median 47.0 31.1 –38.2 46.5 29.9 –26.1
  95% CI – – –44.8 to –29.9 – – –36.7 to –13.5
LDL 5
  Mean (SD) 26.7 (11.8) 16.8 (8.3) –27.8 (57.1) 27.7 (14.7) 15.7 (8.4) –35.6 (37.4) 0.190
  Median 26.2 14.0 –37.2 23.6 12.8 –42.0
  95% CI – – –42.7 to –30.5 – – –52.3 to –33.1
Sum of subfractions 
(LDL 1–5)
  Mean (SD) 146.9 (30.2) 97.3 (30.9) –33.2 (17.7) 150.3 (54.7) 123.1 (34.8) –13.7 (24.7) <0.001
  Median 146.8 94.3 –35.2 138.8 124.8 –14.6
  95% CI – – –39.3 to –30.1 – – –23.6 to –8.0
* Plasma LDL subfractions were fractionated using density gradient ultracentrifugation: LDL 1, 1.019–<1.023 g/mL; LDL 2, 1.023–<1.029 g/mL; LDL 3, 
1.029–<1.039 g/mL; LDL 4, 1.039–<1.050 g/mL; and LDL 5, 1.050–1.063 g/mL.
†Mann-Whitney-Wilcoxon test comparing percentage changes between groups.
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Table IV.  Apolipoprotein (apo) B concentration in each low-density lipoprotein (LDL) subfraction at baseline and at the end of the 
study. Values are mg/dL.
 Atorvastatin 10 mg/d Fenofibrate 200 mg/d 
 (n = 76) (n = 75)
Subfraction* Baseline End of Study % Change Baseline End of Study % Change P†
LDL 1 apoB
  Mean (SD) 10.6 (3.2)  8.3 (3.2) –20.1 (24.1) 10.9 (4.4) 9.4 (2.5) –7.7 (2.3) <0.001
  Median 9.8 7.5 –25.4 9.8 9.6 –6.4
  95% CI – – –28.4 to –16.9 – – –17.6 to –1.0
LDL 2 apoB
  Mean (SD) 11.2 (4.4)  8.6 (4.2) –21.9 (26.3) 12.0 (6.3) 12.6 (4.3) 16.2 (39.9) <0.001
  Median 9.8 7.0 –28.7 10.1 11.9 13.4 
  95% CI – – –35.2 to –22.0 – –  0.0 to 25.4 
LDL 3 apoB
  Mean (SD) 23.2 (10.0) 16.7 (7.0) –24.1 (26.8) 21.1 (9.3) 24.4 (9.0) 33.1 (64.7) <0.001
  Median 21.3 15.8 –27.2 20.1 24.1 15.0
  95% CI – – –38.5 to –17.7 – – 4.5 to 37.9
LDL 4 apoB
  Mean (SD) 32.8 (8.5) 22.8 (8.0) –24.9 (44.4) 30.0 (9.3) 24.0 (11.4) –16.8 (40.9)  0.081
  Median 31.7 22.2 –33.6 29.6 21.4 –23.6
  95% CI – – –41.8 to –25.1 – – –37.2 to –13.4 
LDL 5 apoB
  Mean (SD) 22.5 (9.3) 15.1 (7.2) –22.9 (72.1) 22.3 (11.4) 13.6 (7.3) –28.6 (41.0)  0.441
  Median 21.1 13.8 –31.9 21.8 11.4 –38.1
  95% CI – – –40.2 to –26.0 – – –46.8 to –29.8
Sum of subfractions 
(LDL 1–5 apoB)
  Mean (SD) 100.3 (19.6)  71.4 (19.0) –27.8 (17.7) 96.2 (21.4) 84.0 (23.7) –11.6 (21.9) <0.001
  Median 97.5 68.5 –31.6 96.5 84.0 –12.3
  95% CI – – –35.3 to –25.8 – – –15.6 to –8.2
* Plasma LDL subfractions were fractionated using density gradient ultracentrifugation: LDL 1, 1.019–<1.023 g/mL; LDL 2, 1.023–<1.029 g/mL; LDL 3, 
1.029–<1.039 g/mL; LDL 4, 1.039–<1.050 g/mL; and LDL 5, 1.050–1.063 g/mL.
†  Mann-Whitney-Wilcoxon test comparing percentage changes between groups.
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Figure 2.  Distribution of low-density lipoprotein (LDL) subfractions (based on cholesterol 
content) in the (A) atorvastatin group and the (B) fenofibrate group before 
(baseline) and after treatment. Plasma LDL subfractions were fractionated 
using density gradient ultracentrifugation: LDL 1, 1.019–<1.023 g/mL; LDL 2, 
1.023–<1.029 g/mL; LDL 3, 1.029–<1.039 g/mL; LDL 4, 1.039–<1.050 g/mL; 
and LDL 5, 1.050–1.063 g/mL. Vertical bars represent mean (SD) value of 
relative proportion of each LDL subfraction in terms of cholesterol content. 
*P < 0.001 versus atorvastatin. 
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Table V.  Distribution of low-density lipoprotein (LDL) particle number represented by each LDL subfraction calculated using 
apolipoprotein B concentrations at baseline and at the end of the study. Values are %.
 Atorvastatin 10 mg/d Fenofibrate 200 mg/d 
 (n = 76) (n = 75)
Subfraction* Baseline End of Study Absolute Change Baseline End of Study Absolute Change P†
LDL 1
  Mean (SD) 10.5 (2.3) 11.6 (3.3)  1.1 (3.3) 11.4 (3.8) 11.9 (3.9) 0.5 (3.5)  0.478
  Median 10.1 11.4 0.7 10.8 10.8 0.7
  95% CI – – 0.1 to 1.2 – – –0.2 to 1.2
LDL 2
  Mean (SD) 11.0 (3.2) 12.0 (4.6)  1.0 (3.9) 12.4 (5.0) 15.7 (5.4) 3.3 (4.6) <0.001
  Median 10.2 11.1 0.3 11.0 14.9 3.6
  95% CI – – –0.2 to 1.0 – – 2.2 to 4.4
LDL 3  
  Mean (SD) 22.8 (7.4) 23.3 (7.2)  0.5 (6.3) 21.9 (7.9) 29.1 (6.2) 7.2 (8.3) <0.001
  Median 21.6 23.9 0.8 21.7 29.7 7.4
  95% CI – – –1.5 to 1.9 – – 5.0 to 9.7
LDL 4
  Mean (SD) 32.9 (6.8) 31.9 (6.8) –1.0 (7.9) 31.2 (6.8) 27.6 (7.9) –3.6 (8.6)  0.902
  Median 34.0 31.9 –1.3 32.3 27.9 –3.3
  95% CI – – –2.7 to –0.5 – – –5.6 to –1.1
LDL 5
  Mean (SD) 22.7 (9.3) 21.1 (8.6) –1.6 (7.7) 23.1 (10.6) 15.7 (5.9) –7.4 (9.6) <0.001
  Median 21.2 19.3 –0.6 23.0 14.5 –7.0
  95% CI – – –3.6 to 1.0 – – –7.9 to –3.0
* Plasma LDL subfractions were fractionated by density gradient ultracentrifugation: LDL 1, 1.019–<1.023 g/mL; LDL 2, 1.023–<1.029 g/mL; LDL 3, 
1.029–<1.039 g/mL; LDL 4, 1.039–<1.050 g/mL; and LDL 5, 1.050–1.063 g/mL.
†Mann-Whitney-Wilcoxon test comparing percentage changes between groups.
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The percentage changes in cholesterol (Figure 4) and apoB (Figure 5) concen-
trations in each LDL subfraction according to baseline TG concentrations were 
consistent with the results obtained for the entire study population. Atorvastatin 
treatment was associated with decreases in the cholesterol concentrations 
(27.0%–40.7%) and the apoB concentrations (24.1%–35.9%) in all LDL sub-
classes, with similar effects in normotriglyceridemic (TG <200 mg/dL) and hy-
pertriglyceridemic (TG ≥200 mg/dL) patients. Fenofibrate treatment was associ-
ated with a shift from sdLDL toward larger particles, especially in hyper- 
triglyceridemic patients in whom cholesterol and apoB were both increased in 
LDL 2 (10.2% and 17.3%, respectively) and LDL 3 (20.7% and 26.2%) subfrac-
tions, while they were markedly decreased in LDL 4 (22.8% and 22.9%) and LDL 5 
(44.2% and 41.2%) subfractions.
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Figure 3.  Percentage changes in cholesterol/apolipoprotein (apo) B ratio in each low-
density lipoprotein (LDL) subfraction before (baseline) and after treatment. 
Plasma LDL subfractions were fractionated using density gradient ultracentrifu- 
gation: LDL 1, 1.019–<1.023 g/mL; LDL 2, 1.023–<1.029 g/mL; LDL 3, 
1.029–<1.039 g/mL; LDL 4, 1.039–<1.050 g/mL; and LDL 5, 1.050–1.063 g/mL. 
Vertical bars are median (95% CI). *P < 0.05 versus fenofibrate.
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Figure 4.  Median percentage changes in cholesterol concentrations of each low-density 
lipoprotein (LDL) subfraction before (baseline) and after treatment in (A) patients 
with baseline triglyceride (TG) concentration <200 mg/dL and (B) patients with 
baseline TG ≥200 mg/dL. Plasma LDL subfractions were fractionated using 
density gradient ultracentrifugation: LDL 1, 1.019–<1.023 g/mL; LDL 2, 
1.023–<1.029 g/mL; LDL 3, 1.029–<1.039 g/mL; LDL 4, 1.039–<1.050 g/mL; 
and LDL 5, 1.050–1.063 g/mL.
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Figure 5.  Median percentage changes in apolipoprotein (apo) B concentration in each low-
density lipoprotein (LDL) subfraction before (baseline) and after treatment in (A) pa- 
tients with baseline triglyceride (TG) concentration <200 mg/dL and (B) patients 
with baseline TG ≥200 mg/dL. Plasma LDL subfractions were fractionated using 
density gradient ultracentrifugation: LDL 1, 1.019–<1.023 g/mL; LDL 2, 
1.023–<1.029 g/mL; LDL 3, 1.029–<1.039 g/mL; LDL 4, 1.039–<1.050 g/mL; 
and LDL 5, 1.050–1.063 g/mL.
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Tolerability
Overall, TEAEs were reported in 45 atorvastatin-treated patients (55.6%) and 
44 fenofibrate-treated patients (52.4%). Three patients in the fenofibrate group had 
transient elevated ALT >3 × ULN (including 1 patient with concomitant AST eleva-
tion >3 × ULN, who was withdrawn). In the atorvastatin group, 2 patients were 
withdrawn due to the following AEs: abdominal pain in 1 case and an increase in 
serum CK activity and serum creatinine concentration in a second case. No serious 
AEs related to study treatments were reported. The expected AEs possibly or probably 
related to atorvastatin and fenofibrate treatment were abdominal pain (2 patients 
receiving atorvastatin and 1 patient receiving fenofibrate), abnormal liver function 
test results (1, fenofibrate), gastrointestinal disorders (1, fenofibrate), increased CK 
activity (2, atorvastatin), and vertigo (1, fenofibrate) (Table VI).
DISCUSSION
Because the apoB measurement reflected the number of LDL particles in the sub-
fraction, the cholesterol and apoB concentrations of each LDL subfraction, and not 
the mass of each LDL subfraction, were the selected end points analyzed in this 
study.34,35
The results of this study regarding the effects of atorvastatin and fenofibrate use on 
serum lipid concentrations are consistent with published data.36–38 Fenofibrate use 
was associated with a significantly greater median reduction in TG (41.5%) and a 
significantly greater increase in HDL-C (10.3%) than atorvastatin (decrease of 23.1% 
and increase of 2.8%, respectively). Conversely, although both drugs were associated 
with significant decreases in TC, LDL-C, TC/HDL-C ratio, and apoB plasma concen-
Table VI.  Description of all treatment-emergent adverse events (TEAEs) and TEAEs pos-
sibly or probably related to the study drugs. 
Body System/ Atorvastatin 10 mg/d Fenofibrate 200 mg/d 
Preferred Term* (n = 81) (n = 84)
Any TEAEs 45 44
Any TEAEs possibly or  5 4 
probably related to study drug 
Body as a whole
  Abdominal pain 2 1
Digestive system
  Increased γ-glutamyltransferase activity  1 0
Abnormal liver function test results 0 1
Gastrointestinal disorders 0 1
Metabolic and nutritional disorders
  Increased creatine phosphokinase 2 0
Nervous system
  Vertigo 0 1
* As defined in Coding Symbols for Thesaurus of Adverse Reaction Terms (COSTART).39
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trations, atorvastatin was associated with significantly greater reductions than 
fenofibrate.
Before treatment, patients had asymmetric LDL profiles (based on both cholesterol 
and apoB concentrations), with predominant sdLDL subfractions (mainly the LDL 4 
subfraction) compared with other subfractions. The use of either drug was associated 
with decreased cholesterol in LDL 1 (large LDL) and LDL 4 and 5 (both sdLDL) sub-
fractions. However, the effects of atorvastatin and fenofibrate use on the LDL subfrac-
tion profile differed in terms of percentages, with atorvastatin use being associated 
with homogeneous decreases in all LDL subfractions. In contrast, fenofibrate use 
appeared to shift the distribution of LDL particles from sdLDL (LDL 4 and 5) toward 
larger, lighter ones (LDL 2 and 3). These effects were particularly marked in hyper-
triglyceridemic patients.
These observations made in nondiabetic patients with type IIA or IIB dyslipidemia 
are consistent with previously published findings from a placebo-controlled study in 
hypercholesterolemic patients with type 2 diabetes mellitus25 and from separate as-
sessments of atorvastatin and fenofibrate in 2 small case series in patients with mixed 
dyslipidemia.36,37 In the 2 studies assessing the effect of fenofibrate, the largest de-
creases were found in the mass of LDL 3 particles25 and LDL 4 and 5 particles25,36; 
these decreases were in the same order as the decrease found with fenofibrate in the 
present study in terms of LDL-C content. Similar decreases were also observed in TC 
(–16%), LDL-C (14%), and TG (–44%) concentrations with fenofibrate,36 while re-
ductions in the standard lipids with atorvastatin in the present study were close to 
those observed in the previously mentioned case series study (TC, –31%; LDL-C, 
–36%; and TG, –27%), which did note evidence differential changes in LDL mass.37 
In these previous studies, the evaluation criteria were the LDL mass in each subfrac-
tion, while the present study measured cholesterol content. Assessment of LDL mass 
is more exhaustive, but measurement of cholesterol content seems to provide the same 
information. In addition, Guérin et al36 found that fenofibrate was associated with 
significant reductions in cholesteryl ester transfer protein (CETP) activity. As CETP 
transfers cholesterol from HDL to LDL and TG from LDL to HDL, fenofibrate might 
modify the composition of LDL particles by heterogeneously modifying CETP activi-
ty in the various LDL subfractions.
A randomized, crossover study comparing atorvastatin and fenofibrate at the same 
daily doses as the present study in 11 patients with type 2 diabetes mellitus and 
mixed hyperlipoproteinemia found that atorvastatin was associated with a homoge-
neous decrease in apoB concentration in each LDL subfraction by ~20%, while feno-
fibrate was mainly associated with decreased apoB concentration in the sdLDL sub-
fractions (density 1.041–1.066 g/mL, corresponding to sdLDL) and increased 
concentration in LDL particles with density from 1.030 to 1.040 g/mL (similar to the 
LDL 3 subfraction in the present study [1.029–1.039 g/mL]).40 Thus, fenofibrate 
might act by increasing LDL particle size. Another approach might be to determine 
LDL particle size by measuring the LDL peak particle diameter (the most frequent 
LDL particle diameter). This was done using samples from 405 patients with type 2 
diabetes mellitus in the DAIS (Diabetes Atherosclerosis Intervention Study).41 Feno-
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fibrate use was associated with significantly increased LDL peak size.42 Nuclear mag-
netic resonance (NMR) was also used to evaluate the size of LDL particles in samples 
from a subset of the DAIS population (fenofibrate group, n = 113; placebo group, 
n = 105). Fenofibrate use was also associated with an increase in the size of LDL parti-
cles. NMR determinations of LDL diameter correlated to those measured by GGE, 
although NMR measurements were ~10 nm smaller.43 Despite this bias, NMR mea-
surements had the advantage of providing measurements that are independent of 
LDL-C to predict change in coronary artery angiography.
Two studies that compared the effects of fenofibrate compared with statin drugs 
on LDL size measured by GGE reported similar results.44,45 In a randomized, parallel-
group study comparing the effects of fenofibrate 200 mg versus atorvastatin 
10 mg on apoCIII and lipoprotein-lipid concentrations, including LDL size, LDL 
particle size was measured in 136 dyslipidemic patients.44 Whereas both fenofibrate 
and atorvastatin were associated with increases from baseline in LDL peak particle 
size, the increases were significantly greater with fenofibrate. In another random-
ized, parallel-group study comparing the effects of 16 weeks of treatment with 
fenofibrate (200 mg) and pravastatin (initially 20 mg for 8 weeks, increased to 
40 mg if necessary) on LDL particle size assessed using GGE among patients with 
type IIA dyslipidemia, significant improvements in the plasma TC, LDL-C, 
HDL-C, TG, and apoB were observed with the use of both fenofibrate and prava-
statin, but LDL peak particle size was significantly increased only with fenofibrate. 
Among patients receiving fenofibrate treatment, changes in TG concentration were 
negatively associated with changes in LDL peak particle size (r = –0.54; P < 0.001), 
whereas no such association was found in pravastatin-treated patients. The preva-
lence of patients with sdLDL particles (defined as LDL particle diameter <255.5 Å) 
was reduced from 69.4% to 30.6% (P < 0.05) in fenofibrate-treated patients com-
pared with a reduction from 81.4% to 72.1% (P = NS) in patients who received 
pravastatin.45
Currently, the question of whether cardiovascular risk is related to the size or to the 
number of LDL particles remains unanswered. Recently, El Harchaoui et al46 reported 
in a large epidemiologic cohort study of 25,663 hypercholesterolemic patients that 
the risk for coronary artery disease correlated with both the size and number of par-
ticles. However, the relationship of LDL size to the risk needed to be considered cau-
tiously because the relationship was not found when an adjustment was made for LDL 
particle number. The higher quartile of LDL particle number was associated with a 
1.78-fold (95% CI, 1.34–2.37) higher risk for future cardiovascular events, whereas 
the higher quartile of LDL size was associated with a 40% reduction in risk. In the 
present study, fenofibrate use was associated with modifications of both the size and 
number of LDL particles; redistribution of LDL particles resulted in predominance of 
large LDL particles.
The changes in plasma TG concentrations observed with fenofibrate treatment also 
support previously published observations suggesting that the LDL profile can be 
modulated by changes in TG concentration and that fenofibrate efficacy is strongly 
derived from its hypotriglyceridemic activity.45
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The results from this present study were also consistent with those from previously 
published studies, but on a larger scale and using a randomized, parallel-group design. 
Limitations
A limitation of this study may have been the atorvastatin dosage used (10 mg/d); 
however, studies using higher dosages of atorvastatin (20 or 40 mg/d) reported similar 
results, particularly a similar reduction in LDL particle number across subfractions. 
According to Karalis et al,47 atorvastatin not only decreased the density of LDL par-
ticles, resulting in a shift from sdLDL to more buoyant particles, but the effect was 
dose-dependent. However, atorvastatin 10 mg/d is the dosage recommended to begin 
treatment of dyslipidemia. Moreover, clinical and epidemiologic studies designed to 
assess the effect of atorvastatin on LDL profile and particle size were conducted using 
that same dosage. The application of these results to clinical practice is limited be-
cause the study duration was short (12 weeks), without outcome data and because 
LDL particle profile is not usually determined in that particular setting. However, the 
number of atherogenic particles can be estimated by measuring apoB concentration, 
which is more readily available and believed to offer additional information about 
drug effectiveness beyond LDL-C.48 Analyses of lipoprotein profile and apoB changes 
with fenofibrate use are awaited in intervention studies, such as the FIELD (Fenofi-
brate Intervention and Event Lowering in Diabetes) study,49 to assess the impact of 
reducing sdLDL particles on reduction of cardiovascular events. Cardiovascular 
events were reduced by 27% with fenofibrate 200 mg/d use in those patients with 
TG ≥200 mg/dL, who are more likely to present with an atherogenic LDL profile. 
CONCLUSIONS
This study found that atorvastatin 10 mg/d and fenofibrate 200 mg/d administered 
for 12 weeks were associated with decreases in cholesterol concentrations and the 
number of sdLDL (LDL 4 and 5) particles in these patients with type ll dyslipidemia. 
Fenofibrate treatment was found to induce a significant shift of the LDL profile, with 
significant reductions in sdLDLs (LDL 4 and 5) and a significant increase in LDL 3 
particles, which are considered less atherogenic, especially in hypertriglyceridemic 
patients. In dyslipidemic patients, fenofibrate treatment was associated with improve-
ments in LDL subfraction profile beyond LDL-C reduction, particularly in those pa-
tients with elevated TG concentration, whereas atorvastatin was found to equally re-
duce cholesterol and apoB in all LDL subfractions independent of TG reduction. 
ACKNOWLEDGMENTS
This study was supported by a grant from Laboratoires Fournier SA, Dijon, France.
We thank K. Kirchgassler, P. Aubonnet, and F. Beucher for their advisement on the 
preparation of the manuscript. We also thank the investigators and the patients who 
participated in the study.
Drs. Ansquer and Corda contributed the design and implementation of the study. 
Ms. Le Malicot carried out the statistical analysis. All authors, and in particular, Ms. 
Jessent, contributed to manuscript preparation.
 91
J.-C. Ansquer et al.
Drs. Ansquer and Corda, Ms. Le Malicot and Ms. Jessent are employees of Labo-
ratoires Fournier SA, a Solvay Pharmaceuticals Company that manufactures 
fenofibrate.
REFERENCES
 1. Lindgren FT, Jensen LC, Wills RD, Freeman NK. Flotation rates, molecular weights and hy-
drated densities of the low-density lipoproteins. Lipids. 1969;4:337–344.
 2. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins 
in normal humans. J Lipid Res. 1982;23:97–104.
 3. Swinkels DW, Hak-Lemmers HL, Demacker PN. Single spin density gradient ultracentrifuga-
tion method for the detection and isolation of light and heavy low density lipoprotein subfrac-
tions. J Lipid Res. 1987;28:1233–1239.
 4. Chapman MJ, Laplaud PM, Luc G, et al. Further resolution of the low density lipoprotein 
spectrum in normal human plasma: Physicochemical characteristics of discrete subspecies sepa-
rated by density gradient ultracentrifugation. J Lipid Res. 1988;29:442–458.
 5. McNamara JR, Campos H, Ordovas JM, et al. Effect of gender, age, and lipid status on low 
density lipoprotein subfraction distribution. Results from the Framingham Offspring Study. 
Arteriosclerosis. 1987;7:483–490.
 6. Campos H, Blijlevens E, McNamara JR, et al. LDL particle size distribution. Results from the 
Framingham Offspring Study. Arterioscler Thromb. 1992;12:1410–1419.
 7. Austin MA, Breslow JL, Hennekens CH, et al. Low-density lipoprotein subclass patterns and 
risk of myocardial infarction. JAMA. 1988;260:1917–1921.
 8. Campos H, Genest JJ Jr, Blijlevens E, et al. Low-density lipoprotein particle size and coronary 
artery disease. Arterioscler Thromb. 1992;12:187–195.
 9. Griffin BA, Freeman DJ, Tait GW, et al. Role of plasma triglyceride in the regulation of plasma 
low density lipoprotein (LDL) subfractions: Relative contribution of small, dense LDL to coro-
nary heart disease risk. Atherosclerosis. 1994;106:241–253.
10. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density 
lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882–888.
11. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles 
with the incidence of coronary artery disease in men and women. JAMA. 1996;276:875–881.
12. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a 
predictor of the risk of ischemic heart disease in men. Prospective results from the Québec 
Cardiovascular Study. Circulation. 1997;95:69–75.
13. Feingold KR, Grunfeld C, Pang M, et al. LDL subclass phenotypes and triglyceride metabo-
lism in non-insulin-dependent diabetes. Arterioscler Thromb. 1992;12:1496–1502.
14. Austin MA. Low-density lipoprotein subclass phenotypes and familial combined hyperlipi-
demia. Diabetes Metab Rev. 1991;7:173–177.
15. Hunt SC, Wu LL, Hopkins PN, et al. Apolipoprotein, low density lipoprotein subfraction, and 
insulin associations with familial combined hyperlipidemia. Study of Utah patients with famil-
ial dyslipidemic hypertension. Arteriosclerosis. 1989;9:335–344.
16. Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with dimin-
ished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res. 1993;34:295– 
308.
17. Swinkels DW, Demacker PN, Hendriks JC, van ’t Laar A. Low density lipoprotein subfractions 
and relationship to other risk factors for coronary artery disease in healthy individuals [pub-
lished correction appears in Arteriosclerosis. 1990;10:491]. Arteriosclerosis. 1989;9:604–613.
Current Therapeutic Research
92
18. Coresh J, Kwiterovich PO Jr, Smith HH, Bachorik PS. Association of plasma triglyceride 
concentration and LDL particle diameter, density, and chemical composition with premature 
coronary artery disease in men and women. J Lipid Res. 1993;34:1687–1697.
19. St-Pierre AC, Cantin B, Dagenais GR, et al. Low-density lipoprotein subfractions and the long-
term risk of ischemic heart disease in men: 13-Year follow-up data from the Québec Cardiovas-
cular Study. Arterioscler Thromb Vasc Biol. 2005;25:553–559. 
20. Lamarche B, St-Pierre AC, Ruel IL, et al. A prospective, population-based study of low density 
lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol. 
2001;17:859–865.
21. St-Pierre AC, Ruel IL, Cantin B, et al. Comparison of various electrophoretic characteristics of 
LDL particles and their relationship to the risk of ischemic heart disease. Circulation. 
2001;104:2295–2299.
22. Campos H, Moye LA, Glasser SP, et al. Low-density lipoprotein size, pravastatin treatment, and 
coronary events. JAMA. 2001;286:1468–1474.
23. Newcombe RG. Interval estimation for the difference between independent proportions: Com-
parison of eleven methods [published correction appears in Stat Med. 1999;18:1293]. Stat Med. 
1998;17:873–890.
24. Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterio-
scler Thromb Vasc Biol. 1997;17:3542–3556.
25. Feher MD, Caslake M, Foxton J, et al. Atherogenic lipoprotein phenotype in type 2 diabetes: 
Reversal with micronised fenofibrate. Diabetes Metab Res Rev. 1999;15:395–399.
26. Rizzo M, Berneis K. The clinical relevance of low-density lipoproteins size modulation by 
statins. Cardiovasc Drugs Ther. 2006;20:205–217.
27. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% 
in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase 
inhibitor. Arterioscler Thromb Vasc Biol. 1995;15:678–682.
28. Ooi TC, Heinonen T, Alaupovic P, et al. Efficacy and safety of a new hydroxymethylglutaryl-
coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: 
Comparison with fenofibrate. Arterioscler Thromb Vasc Biol. 1997;17:1793–1799.
29. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 
Executive Summary of the Third Report of the National Cholesterol Education Program 
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in 
Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497.
30. European Agency for the Evaluation of Medicinal Products, International Conference on 
Harmonisation–World Health Organization. Guideline for Good Clinical Practice. [EMEA 
Web site]. ICH Topic E6. Geneva, Switzerland: WHO; 2002. http://www.emea.eu.int. Accessed 
February 23, 2009.
31. World Medical Association Declaration of Helsinki: Recommendations Guiding Medical Doc-
tors in Biomedical Research Involving Human Subjects [WMA Web site]. Ferney-Voltaire, 
France: WMA; 1989. http://www.wma.net. Accessed February 23, 2009.
32. Luc G, Bard JM, Ferrières J, et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein 
A-I and lipoprotein A-I/A-II in prediction of coronary heart disease: The PRIME Study (Pro-
spective Epidemiological Study of Myocardial Infarction). Arterioscler Thromb Vasc Biol. 
2002;22:1155–1161.
33. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density 
lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 
1972;18:499–502.
34. Sniderman AD. How, when, and why to use apolipoprotein B in clinical practice. Am J Cardiol. 
2002;90:48i–54i.
 93
J.-C. Ansquer et al.
35. Sniderman AD, Furberg CD, Keech A, et al. Apolipoproteins versus lipids as indices of coro-
nary risk and as targets for statin treatment. Lancet. 2003;361:777–780.
36. Guérin M, Bruckert E, Dolphin PJ, et al. Fenofibrate reduces plasma cholesteryl ester transfer 
from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipi-
demia. Arterioscler Thromb Vasc Biol. 1996;16:763–772.
37. Guerin M, Lassel TS, Le Goff W, et al. Action of atorvastatin in combined hyperlipidemia: 
Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler 
Thromb Vasc Biol. 2000;20:189–197.
38. Winkler K, Weltzien P, Friedrich I, et al. Qualitative effect of fenofibrate and quantitative ef-
fect for atorvastatin on LDL profile in combined hyperlipidemia with dense LDL. Exp Clin 
Endocrinol Diabetes. 2004;112:241–247.
39. US Food and Drug Administration. Medical Dictionary for Regulatory Activities [MedDRA 
Web site] [formerly COSTART]. http://www.meddramsso.com/MSSOWeb/index.htm. Ac-
cessed January 12, 2009. 
40. Frost RJ, Otto C, Geiss HC, et al. Effects of atorvastatin versus fenofibrate on lipoprotein pro-
files, low density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 
diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol. 2001;87:44–48.
41. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression 
of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, 
a randomised study. Lancet. 2001;357:905–910.
42. Vakkilainen J, Steiner G, Ansquer JC, et al, for the DAIS Group. Relationships between low-
density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: 
The Diabetes Atherosclerosis Intervention Study (DAIS). Circulation. 2003;107:1733–1737.
43. Steiner G, Otvos J, Vakkilainen J, et al. Fenofibrate and lipoprotein size in type 2 diabetes, 
evaluated by NMR and comparison to gradient gel electrophoresis (GGE) determinations. Dia-
betologia. 2003;46:A74. Abstract.
44. Lemieux I, Salomon H, Després JP. Contribution of apo CIII reduction to the greater effect of 
12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size 
in dyslipidemic patients. Ann Med. 2003;35:442–448.
45. Lemieux I, Laperrière L, Dzavik V, et al. A 16-week fenofibrate treatment increases LDL par-
ticle size in type IIA dyslipidemic patients. Atherosclerosis. 2002;162:363–371.
46. El Harchaoui K, van der Steeg WA, Stroes ES, et al. Value of low-density lipoprotein particle 
number and size as predictors of coronary artery disease in apparently healthy men and women: 
The EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;49:547–553.
47. Karalis DG, Ishisaka DY, Luo D, et al. Effects of increasing doses of atorvastatin on the athero-
genic lipid subclasses commonly associated with hypertriglyceridemia. Am J Cardiol. 2007; 
100:445–449.
48. Williams K, Sniderman AD, Sattar N, et al. Comparison of the associations of apolipoprotein 
B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin 
Resistance Atherosclerosis Study (IRAS). Circulation. 2003;108:2312–2316.
49. Scott R, O’Brien R, Fulcher G, et al, for the FIELD Study Investigators. The effects of fenofi-
brate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various 
components of the metabolic syndrome: The FIELD study [online publication ahead of print 
November 4, 2008]. Diabetes Care.
Address correspondence to: Jean-Claude Ansquer, MD, Laboratoires 
Fournier SA, 50 rue de Dijon, 21 121 Daix, France. E-mail: jean-claude.ansquer@
solvay.com
